Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-1010
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol ; volume:27 ; number:1 ; day:23 ; month:10 ; year:2017 ; pages:1-6 ; date:12.2017
npj Primary care respiratory medicine ; 27, Heft 1 (23.10.2017), 1-6, 12.2017
- Creator
-
Koch, Andrea
Watz, Henrik
Maleki-Yazdi, M. Reza
Bothner, Ulrich
Tetzlaff, Kay
Voß, Florian
McGarvey, Lorcan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41533-017-0059-1
- URN
-
urn:nbn:de:101:1-2019102019474030904943
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Koch, Andrea
- Watz, Henrik
- Maleki-Yazdi, M. Reza
- Bothner, Ulrich
- Tetzlaff, Kay
- Voß, Florian
- McGarvey, Lorcan
- SpringerLink (Online service)
Other Objects (12)
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Development of long-acting ARV’s
Formoterol : a long-acting β2-agonist for the management of asthma ; an international symposium, held during the joint meeting of SEP and SEPCR, London, 1990
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Creation of a long-acting nanoformulated dolutegravir
Long-Acting Reversible Contraception
Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Development of long-acting ARV’s
Formoterol : a long-acting β2-agonist for the management of asthma ; an international symposium, held during the joint meeting of SEP and SEPCR, London, 1990
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Creation of a long-acting nanoformulated dolutegravir
Long-Acting Reversible Contraception
Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Development of long-acting ARV’s
Formoterol : a long-acting β2-agonist for the management of asthma ; an international symposium, held during the joint meeting of SEP and SEPCR, London, 1990
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Creation of a long-acting nanoformulated dolutegravir
Long-Acting Reversible Contraception
Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD